SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 8, 2018
THE COOPER COMPANIES, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
6140 Stoneridge Mall Road, Suite 590, Pleasanton, California 94588
(Address of principal executive offices, including Zip Code)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financing accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 8, 2018, The Cooper Companies, Inc. (the Company) announced that its Board of Directors (its Board) has named Albert G. White III as the President and Chief Executive Officer (CEO) of the Company, effective May 1, 2018. Mr. White will succeed Robert S. Weiss, who will retire as President and CEO, effective April 30, 2018.
Mr. White, 49, has served as Chief Financial Officer since November 2016. He also serves as Executive Vice President and Chief Strategy Officer, positions he has held since December 2015 and July 2011, respectively. Since August 2015, Mr. White also oversees and directs our womens healthcare business and is currently CEO of Cooper Medical, Inc., the parent company to CooperSurgical, Inc. Previously, he served as Vice President, Investor Relations from November 2007 through March 2013 and as Vice President and Treasurer from April 2006 through December 2012. Prior to joining the Company, Mr. White was a Director with KeyBanc Capital Markets for three years and held a number of leadership positions within KeyBank National Association over the prior eight years.
Mr. Whites current compensation is set forth in the Companys proxy statement filed with the Securities Exchange Commission on February 2, 2018.
ITEM 7.01. Regulation FD Disclosure.
On March 8, 2018, the Company issued a press release announcing the appointment of Mr. White and the retirement of Mr. Weiss. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Internet addresses in the release are for information purposes only and are not intended to be hyperlinks to other The Cooper Companies, Inc. information.
The information in this report furnished pursuant to Item 7.01, including Exhibit 99.1 attached hereto, will not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this Current Report on Form 8-K.
ITEM 9.01. Financial Statements and Exhibits.
|99.1||Press Release dated March 8, 2018, of The Cooper Companies, Inc.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|THE COOPER COMPANIES, INC.|
|Dated: March 9, 2018||By:||/s/ Albert G. White, III|
|Albert G. White, III|
Executive Vice President, Chief Financial Officer
and Chief Strategy Officer
March 8, 2018
Albert White to Succeed Robert Weiss as CEO of the Cooper Companies
Weiss to Retire; Remain on Board of Directors
PLEASANTON, Calif., March 8, 2018 The Cooper Companies, Inc. (NYSE: COO) today announced that its Board of Directors has named Albert G. White III President and Chief Executive Officer of The Cooper Companies effective May 1, 2018. Mr. White will succeed Robert S. Weiss who will retire as President and Chief Executive Officer on April 30, 2018, and then act in an advisory capacity until December 31, 2018, to ensure a smooth transition. Mr. White has held a number of senior management roles in the Company including most recently Executive Vice President, Chief Financial Officer, Chief Strategy Officer and CEO of Cooper Medical, Inc., the holding company for CooperSurgical.
Commenting on the transition, A. Thomas Bender, Chairman of the Companys Board, said, On behalf of the Board, we thank Bob for his leadership and accomplishments for the last 40 plus years, and in particular his stewardship of Cooper over the last 10 plus years as CEO. Through his leadership, the Company has grown to over $12 billion in market value, built strong franchises and organizations in its CooperVision and CooperSurgical businesses and become a member of the S&P 500. Bob joined Cooper in 1977 and has held many senior management positions within the Company including Chief Operating Officer, Chief Financial Officer and President of CooperVision. Notably, his continued commitment to succession planning culminated in the decision to name Al as the next CEO. We are all highly confident in Als ability to lead Coopers growth and he has the full support of the Board of Directors.
Al joined Cooper in 2006 and has helped lead and execute many of the Companys investments and strategic decisions. Commenting on the news, he noted Bobs dedication, leadership and contributions to Cooper have been exceptional, and he has positioned us well for continued growth in both our vision and womens healthcare businesses. Our financial strength, global reach and innovative products and services are a proud legacy for Bob and a strong foundation for the future of Cooper. I am privileged and very excited to lead the organization going forward.
This is the perfect time for Al to become Coopers next CEO. He is a very strong leader and I am confident he will continue driving Coopers success. said Mr. Weiss. Serving as President and CEO of Cooper has been a privilege and I would like to thank all our employees for their commitment and dedication. It has been an honor to lead such an outstanding organization, and I look forward to continuing to serve on the Board.
About The Cooper Companies
The Cooper Companies, Inc. (Cooper) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper is dedicated to being A Quality of Life Company with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of families with its diversified portfolio of products and services focusing on womens health, fertility and diagnostics. Headquartered in Pleasanton, CA, Cooper has more than 11,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including our 2018 Guidance and all statements regarding acquisitions including the acquired companies financial position, market position, product development and business strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and the acquired entities future expenses, sales and diluted earnings per share are forward looking. In addition, all statements regarding anticipated growth in our revenue, anticipated effects of any product recalls, anticipated market conditions, planned product launches and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like believes, expects, may, will, should, could, seeks, intends, plans, estimates or anticipates and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.
Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions, including the impact of continuing uncertainty and instability of certain countries that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items, including but not limited to, the United Kingdoms election to withdraw from the European Union; changes in tax laws or their interpretation and changes in statutory tax rates, including but not limited to, United States and other countries with proposed changes to tax laws, some of which may affect our taxation of earnings recognized in foreign jurisdictions and/or negatively impact our effective tax rate; our existing indebtedness and associated interest expense, most of which is variable and impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our revenues and earnings; acquisition-related adverse effects including the failure to successfully obtain the anticipated revenues, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to integration of acquisitions, natural disasters, system upgrades or other causes; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry including the contact lens industry specifically and the medical device or pharmaceutical industries generally; compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of third party information, such as HIPAA in the U.S. and the pending General Data Protection Regulation requirements which are to take effect in Europe on May 25, 2018, including but not limited to those resulting from data security breaches; legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement or other litigation; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies, including but not limited
to, technological advances by competitors, new products and patents attained by competitors, and competitors expansion through acquisitions; reduced sales, loss of customers and costs and expenses related to product recalls and warning letters; failure to receive, or delays in receiving, U.S. or foreign regulatory approvals for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third party payors for our products and services; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, and idle manufacturing facilities and equipment; the success of our research and development activities and other start-up projects; dilution to earnings per share from acquisitions or issuing stock; changes in accounting principles or estimates; environmental risks; and other events described in our Securities and Exchange Commission filings, including the Business and Risk Factors sections in the Companys Annual Report on Form 10-K for the fiscal year ended October 31, 2017, as such Risk Factors may be updated in quarterly filings.
We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.
Source: The Cooper Companies, Inc.
Vice President, Investor Relations
The Cooper Companies, Inc.
Source: The Cooper Companies, Inc.
News Provided by Acquire Media